Severe Hypertriglyceridemia

Pipeline Programs

Companies

Clinical Trials

2 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic

3100%

+ 6 programs with unclassified modality

On Market (1)

Approved therapies currently available

REDEMPLOApproved

plozasiran

Arrowhead Pharmaceuticals

APOC-III-directed RNA Interaction [EPC]subcutaneous2025

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Arrowhead PharmaceuticalsPASADENA, CA

2 programs

REDEMPLO(plozasiran)Phase 35 trials

ARO-APOC3Phase 21 trial

Active Trials

NCT04720534Completed229Est. Aug 2023

NCT06796426Available

NCT06880770Recruiting288Est. Jun 2029

+3 more trials

AstraZenecaCAMBRIDGE, United Kingdom

2 programs

EpanovaPhase 21 trial

EpanovaPhase 11 trial

Active Trials

NCT02189252Completed30Est. Jul 2015

NCT01208961Completed54Est. Nov 2010

Doer BiologicsChina - Hangzhou

1 program

DR10624 InjectionPhase 21 trial

Active Trials

NCT06555640Completed79Est. Aug 2025

Prevail TherapeuticsNY - New York

1 program

SolbinsiranPhase 2

Ionis PharmaceuticalsCARLSBAD, CA

3 programs

OlezarsenPHASE_3RNA Therapeutic1 trial

Active Trials

NCT05681351Active Not Recruiting885Est. Mar 2027

NCT05552326Completed446Est. Sep 2025

NCT05079919Completed617Est. Jul 2025

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

2029

Arrowhead Pharmaceuticalsplozasiran

Ionis PharmaceuticalsOlezarsen

Arrowhead Pharmaceuticalsplozasiran

Ionis PharmaceuticalsOlezarsen

Doer BiologicsDR10624 Injection

Arrowhead Pharmaceuticalsplozasiran

Arrowhead PharmaceuticalsARO-APOC3

AstraZenecaEpanova

Clinical Trials (16)

Total enrollment: 6,175 patients across 16 trials

NCT06880770 Arrowhead Pharmaceuticalsplozasiran

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

Start: Apr 2025Est. completion: Jun 2029288 patients

Phase 3Recruiting

NCT06822790 Arrowhead Pharmaceuticalsplozasiran

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

Start: Apr 2025Est. completion: Jul 2028869 patients

Phase 3Recruiting

NCT06347016 Arrowhead Pharmaceuticalsplozasiran

Study of Plozasiran in Adults With Severe Hypertriglyceridemia

Start: Jul 2024Est. completion: Sep 2026311 patients

Phase 3Active Not Recruiting

NCT06347003 Arrowhead Pharmaceuticalsplozasiran

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Start: Jul 2024Est. completion: Sep 2026446 patients

Phase 3Active Not Recruiting

NCT06347133 Arrowhead Pharmaceuticalsplozasiran

Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Start: May 2024Est. completion: Sep 20261,456 patients

Phase 3Active Not Recruiting

NCT05902598 Arrowhead Pharmaceuticalsplozasiran

A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome

Start: Jul 2023Est. completion: Jan 202637 patients

Phase 3Completed

NCT05681351 Ionis PharmaceuticalsOlezarsen

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

Start: Dec 2022Est. completion: Mar 2027885 patients

Phase 3Active Not Recruiting

NCT05552326 Ionis PharmaceuticalsOlezarsen

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

Start: Aug 2022Est. completion: Sep 2025446 patients

Phase 3Completed

NCT05089084 Arrowhead Pharmaceuticalsplozasiran

Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Start: Dec 2021Est. completion: Apr 202675 patients

Phase 3Active Not Recruiting

NCT05079919 Ionis PharmaceuticalsOlezarsen

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

Start: Oct 2021Est. completion: Jul 2025617 patients

Phase 3Completed

NCT06555640 Doer BiologicsDR10624 Injection

A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia

Start: Aug 2024Est. completion: Aug 202579 patients

Phase 2Completed

NCT04998201 Arrowhead Pharmaceuticalsplozasiran

Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia

Start: Sep 2021Est. completion: Aug 2023353 patients

Phase 2Completed

NCT04720534 Arrowhead PharmaceuticalsARO-APOC3

Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

Start: May 2021Est. completion: Aug 2023229 patients

Phase 2Completed

NCT01208961 AstraZenecaEpanova

Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation

Start: Sep 2010Est. completion: Nov 201054 patients

Phase 2Completed

NCT02189252 AstraZenecaEpanova

An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis

Start: Oct 2014Est. completion: Jul 201530 patients

Phase 1Completed

NCT06796426 Arrowhead Pharmaceuticalsplozasiran

Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS

N/AAvailable

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals

2 actively recruiting trials targeting 6,175 patients

6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.